TTRXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Turn Therapeutics Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$10.74+0.17 (+1.61%)

Close on Oct 19, 2026

Market cap: $319.92M
P/E (TTM): –
Dividend yield: –

Turn Therapeutics Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31
Stock-Based Compensation	0.42	0.28	0.26	0.04	0.05	0.08	0.04
Change in Accounts Payable	0.29	-0.61	0.66	1.25	0.37	-0.02	0.05
Operating Cash Flow	-0.92	-1.63	-1.18	-0.59	-0.50	-0.30	-0.43
Investing Cash Flow	-0.01	-0.01	-0.03	-0.09	–	–	-0.01
Stock Issued	–	–	3.18	0.59	2.15	1.00	0.52
Financing Cash Flow	0.00	7.79	3.18	0.59	2.15	1.00	0.52

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -141.7%

Financial strength

Current ratio: 1.19
Debt to equity: 8.83
Debt to assets: 35.7%
Cash to current liabilities: 113.5%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 465.76
Dividend yield: –